×
S&P 500   3,886.08 (-0.36%)
DOW   31,419.91 (-0.06%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   261.85 (-1.15%)
META   168.32 (-0.69%)
GOOGL   2,283.66 (-1.42%)
AMZN   110.39 (-2.50%)
TSLA   724.97 (-1.33%)
NVDA   164.46 (-2.51%)
NIO   22.29 (-2.88%)
BABA   118.84 (+0.09%)
AMD   82.72 (-3.99%)
MU   59.41 (+1.07%)
CGC   3.73 (-1.58%)
T   20.93 (+0.72%)
GE   67.15 (+0.66%)
F   12.16 (+1.00%)
DIS   99.76 (+3.26%)
AMC   13.61 (-3.68%)
PFE   51.39 (-0.94%)
PYPL   74.74 (-1.58%)
NFLX   185.61 (-1.87%)
S&P 500   3,886.08 (-0.36%)
DOW   31,419.91 (-0.06%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   261.85 (-1.15%)
META   168.32 (-0.69%)
GOOGL   2,283.66 (-1.42%)
AMZN   110.39 (-2.50%)
TSLA   724.97 (-1.33%)
NVDA   164.46 (-2.51%)
NIO   22.29 (-2.88%)
BABA   118.84 (+0.09%)
AMD   82.72 (-3.99%)
MU   59.41 (+1.07%)
CGC   3.73 (-1.58%)
T   20.93 (+0.72%)
GE   67.15 (+0.66%)
F   12.16 (+1.00%)
DIS   99.76 (+3.26%)
AMC   13.61 (-3.68%)
PFE   51.39 (-0.94%)
PYPL   74.74 (-1.58%)
NFLX   185.61 (-1.87%)
S&P 500   3,886.08 (-0.36%)
DOW   31,419.91 (-0.06%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   261.85 (-1.15%)
META   168.32 (-0.69%)
GOOGL   2,283.66 (-1.42%)
AMZN   110.39 (-2.50%)
TSLA   724.97 (-1.33%)
NVDA   164.46 (-2.51%)
NIO   22.29 (-2.88%)
BABA   118.84 (+0.09%)
AMD   82.72 (-3.99%)
MU   59.41 (+1.07%)
CGC   3.73 (-1.58%)
T   20.93 (+0.72%)
GE   67.15 (+0.66%)
F   12.16 (+1.00%)
DIS   99.76 (+3.26%)
AMC   13.61 (-3.68%)
PFE   51.39 (-0.94%)
PYPL   74.74 (-1.58%)
NFLX   185.61 (-1.87%)
S&P 500   3,886.08 (-0.36%)
DOW   31,419.91 (-0.06%)
QQQ   290.76 (-0.58%)
AAPL   140.87 (-0.56%)
MSFT   261.85 (-1.15%)
META   168.32 (-0.69%)
GOOGL   2,283.66 (-1.42%)
AMZN   110.39 (-2.50%)
TSLA   724.97 (-1.33%)
NVDA   164.46 (-2.51%)
NIO   22.29 (-2.88%)
BABA   118.84 (+0.09%)
AMD   82.72 (-3.99%)
MU   59.41 (+1.07%)
CGC   3.73 (-1.58%)
T   20.93 (+0.72%)
GE   67.15 (+0.66%)
F   12.16 (+1.00%)
DIS   99.76 (+3.26%)
AMC   13.61 (-3.68%)
PFE   51.39 (-0.94%)
PYPL   74.74 (-1.58%)
NFLX   185.61 (-1.87%)
NASDAQ:ALBO

Albireo Pharma Stock Forecast, Price & News

$19.01
-0.35 (-1.81%)
(As of 06/28/2022 11:09 AM ET)
Add
Compare
Today's Range
$19.01
$19.28
50-Day Range
$18.65
$35.57
52-Week Range
$17.81
$37.86
Volume
494 shs
Average Volume
266,072 shs
Market Capitalization
$368.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$72.67
30 days | 90 days | 365 days | Advanced Chart

Receive ALBO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Albireo Pharma and its competitors with MarketBeat's FREE daily newsletter.

ALBO Stock Forecast (MarketRank)

Overall MarketRank

2.20 out of 5 stars

Medical Sector

365th out of 1,436 stocks

Pharmaceutical Preparations Industry

159th out of 687 stocks

Analyst Opinion: 3.5Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
Albireo Pharma logo

About Albireo Pharma (NASDAQ:ALBO)

Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

ALBO Stock News Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ALBO
Employees
130
Year Founded
2003

Company Calendar

Last Earnings
5/16/2022
Today
6/28/2022
Next Earnings (Estimated)
8/04/2022
Fiscal Year End
12/31/2022

Price Target and Rating

Average Stock Price Forecast
$72.67
High Stock Price Forecast
$80.00
Low Stock Price Forecast
$66.00
Forecasted Upside/Downside
+282.3%
Consensus Rating
Buy
Rating Score (0-4)
3
Research Coverage
3 Analysts

Profitability

Net Income
$-34.03 million
Pretax Margin
-72.02%

Debt

Sales & Book Value

Annual Sales
$40.58 million
Book Value
$9.11 per share

Miscellaneous

Free Float
18,239,000
Market Cap
$368.03 million
Optionable
Optionable
Beta
0.98

Social Links















Albireo Pharma Frequently Asked Questions

Should I buy or sell Albireo Pharma stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Albireo Pharma stock.
View analyst ratings for Albireo Pharma
or view top-rated stocks.

What is Albireo Pharma's stock price forecast for 2022?

3 Wall Street analysts have issued 1-year price objectives for Albireo Pharma's stock. Their ALBO stock forecasts range from $66.00 to $80.00. On average, they expect Albireo Pharma's share price to reach $72.67 in the next year. This suggests a possible upside of 276.9% from the stock's current price.
View analysts' price targets for Albireo Pharma
or view top-rated stocks among Wall Street analysts.

How has Albireo Pharma's stock price performed in 2022?

Albireo Pharma's stock was trading at $23.29 at the beginning of the year. Since then, ALBO shares have decreased by 17.2% and is now trading at $19.28.
View the best growth stocks for 2022 here
.

Are investors shorting Albireo Pharma?

Albireo Pharma saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 1,530,000 shares, an increase of 35.4% from the May 31st total of 1,130,000 shares. Based on an average trading volume of 287,700 shares, the days-to-cover ratio is presently 5.3 days. Approximately 17.1% of the company's shares are short sold.
View Albireo Pharma's Short Interest
.

When is Albireo Pharma's next earnings date?

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Albireo Pharma
.

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) released its earnings results on Monday, May, 16th. The biopharmaceutical company reported ($2.19) earnings per share for the quarter, missing the consensus estimate of ($2.02) by $0.17. Albireo Pharma had a negative net margin of 72.02% and a negative trailing twelve-month return on equity of 73.93%. During the same quarter in the previous year, the company earned ($2.29) EPS.
View Albireo Pharma's earnings history
.

Who are Albireo Pharma's key executives?

Albireo Pharma's management team includes the following people:
  • Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 59, Pay $1.1M)
  • Mr. Simon Nicolas Reade Harford, CFO & Treasurer (Age 61, Pay $687.78k)
  • Ms. Martha J. Carter, Chief Regulatory Officer (Age 70, Pay $710.69k)
  • Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.
  • Dr. Jan P. Mattsson Ph.D., Chief Scientific Officer, MD (Sweden) & Co-Founder (Age 58)
  • Ms. Joan Connolly, Chief Technology Officer
  • Mr. Jason G. Duncan, Chief Legal Officer, Gen. Counsel & Sec. (Age 48) (LinkedIn Profile)
  • Ms. Michelle Graham, Chief HR Officer (Age 55)
  • Dr. Kristina Torfgard, VP & Global Project Head
  • Ms. Pamela Stephenson M.P.H., Chief Commercial Officer (Age 54) (LinkedIn Profile)

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (5.94%), Chicago Capital LLC (5.23%), Vanguard Group Inc. (5.05%), State Street Corp (4.69%), Decheng Capital Management III Cayman LLC (2.68%) and Prosight Management LP (2.48%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford.
View institutional ownership trends for Albireo Pharma
.

Which institutional investors are selling Albireo Pharma stock?

ALBO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., State Street Corp, Platinum Investment Management Ltd., Citigroup Inc., Prosight Management LP, Privium Fund Management B.V., BlackRock Inc., and Bank of America Corp DE. Company insiders that have sold Albireo Pharma company stock in the last two years include Jan Mattsson, Jason Duncan, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Ronald Harold Wilfred Cooper, and Simon NR Harford.
View insider buying and selling activity for Albireo Pharma
or view top insider-selling stocks.

Which institutional investors are buying Albireo Pharma stock?

ALBO stock was acquired by a variety of institutional investors in the last quarter, including Decheng Capital Management III Cayman LLC, Nicholas Investment Partners LP, Chicago Capital LLC, Prudential Financial Inc., MAI Capital Management, Endurant Capital Management LP, Vanguard Group Inc., and Dimensional Fund Advisors LP.
View insider buying and selling activity for Albireo Pharma
or or view top insider-buying stocks.

How do I buy shares of Albireo Pharma?

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $19.28.

How much money does Albireo Pharma make?

Albireo Pharma (NASDAQ:ALBO) has a market capitalization of $373.26 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34.03 million in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does Albireo Pharma have?

Albireo Pharma employs 130 workers across the globe.

When was Albireo Pharma founded?

Albireo Pharma was founded in 2003.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The official website for Albireo Pharma is www.albireopharma.com. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at [email protected], or via fax at 203-796-5001.

This page (NASDAQ:ALBO) was last updated on 6/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.